Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Ovarian Cancer | Unmet Need | US/EU | 2017

Login to access report north_east
Contact sales account_box

Platinum-based chemotherapy has remained the standard of care for the treatment of platinum-sensitive ovarian cancer, but new classes of drugs such as angiogenesis inhibitors and more recently PARP inhibitors, have entered the therapeutic landscape for this indication. Due to the regulatory approval of targeted therapies, such as Roche/Genentech’s Avastin, AstraZeneca’s Lynparza, Tesaro’s Zejula, and Clovis Oncology’s Rubraca, the market is more crowded leading to higher barriers of entry for emerging therapies in platinum-sensitive ovarian cancer. However, areas of unmet need for the treatment of platinum-sensitive ovarian cancer remain. This content evaluates the key drivers of prescribing and analyzes the areas of significant commercial opportunities that could be valuable commercial opportunities for developers.

Questions Answered:

  • What are the treatment drivers and goals for platinum-sensitive ovarian cancer?
  • What attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for platinum-sensitive ovarian cancer?
  • What are the prevailing areas of unmet need and opportunity in platinum-sensitive ovarian cancer?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European medical oncologists for a hypothetical new therapy for platinum-sensitive ovarian cancer?

Markets covered: United States, United Kingdom, France, and Germany.

Primary research: Survey of 61 U.S. and 30 European medical oncologists fielded in April 2017.

Key companies: Roche/Genentech, AstraZeneca, Tesaro, Clovis Oncology.

Key drugs: Carboplatin/Paclitaxel, Avastin, Lynparza, Zejula, Rubraca.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Chronic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Back Pain (US)
Approximately 30 million people in the United States have chronic back pain (CBP). Treatment of CBP poses a challenge to physicians owing to the heterogeneity of pain pathophysiology and the…
north_east
Report
Post-Traumatic Stress Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Post-Traumatic Stress Disorder (US)
Multiple guidelines recommend treating post-traumatic stress disorder (PTSD) first with psychotherapy. However, such approaches do not suffice for many patients, necessitating the use of…
north_east
Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
north_east
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
north_east
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east